44.41 0.00 (0.00%)
After hours: 5:06PM EDT
|Bid||44.41 x 800|
|Ask||44.42 x 1100|
|Day's Range||43.89 - 44.75|
|52 Week Range||33.80 - 69.43|
|Beta (3Y Monthly)||2.24|
|PE Ratio (TTM)||18.99|
|Earnings Date||Jul 31, 2019 - Aug 5, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||49.00|
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
Looking for stocks with high upside potential? Just follow the big players within the hedge fund industry. Why should you do so? Let’s take a brief look at what statistics have to say about hedge funds’ stock picking abilities to illustrate. The Standard and Poor’s 500 Index returned approximately 12.1% in 2019 (through May 30th). Conversely, hedge […]
Cambrex Corporation (CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced three senior appointments to further support the company’s strategy to create the Contract Development and Manufacturing Organization (CDMO) of choice for small molecules within the pharmaceutical industry. Bruno Biscaro has been appointed President, Drug Products. In this new role, he will have global responsibility for the company’s drug product business.
Cambrex Corporation (CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced that Dottie Donnelly-Brienza has been appointed Senior Vice President and Chief Human Resources Officer. In this new role, she will have global responsibility for the company’s human resources function, and will join the company’s executive management team. Ms. Brienza has over 20 years’ HR experience in the life sciences sector, and joins Cambrex from Cantel Medical where she was most recently Chief Human Resources Officer.
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Cambrex Corporation...
Cambrex Corp NYSE:CBMView full report here! Summary * Bearish sentiment is moderate * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is moderate for CBM with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold CBM had net inflows of $924 million over the last one-month. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Basic Materials sector is rising. The rate of growth is weak relative to the trend shown over the past year, but is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Cambrex Corporation (CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced that it has completed a new 600 m2 facility at its site in Karlskoga, Sweden, which incorporates new laboratories for process and analytical development. The new, three-story building will incorporate process technology, QC and analytical development laboratories. The process technology laboratories will expand capacity providing an area where R&D and production teams can work together on scale up demonstration and technology transfer, including new capabilities in the scaling up of potent molecules requiring containment. The facility will employ computer modeling to optimize reactor set ups and plant conditions to improve technology transfer and the performance of existing processes.
EAST RUTHERFORD, N.J., May 29, 2019 -- Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services across.
The Zacks Analyst Blog Highlights: Cambrex, Innoviva, Celgene, BioDelivery Sciences International and Unity Biotechnology
Cambrex (CBM) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Cambrex (CBM) delivered earnings and revenue surprises of 17.65% and -0.75%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The East Rutherford, New Jersey-based company said it had net income of 31 cents per share. Earnings, adjusted for non-recurring costs and stock option expense, came to 60 cents per share. The results ...
- Acquired Avista Pharma Solutions, broadening capabilities, enhancing revenue growth and expanding customer base - - Reaffirms full year financial guidance - - Conference.
EAST RUTHERFORD, N.J., April 30, 2019 -- Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services.